|Bid||46.78 x 2900|
|Ask||46.84 x 1100|
|Day's range||46.79 - 47.54|
|52-week range||44.30 - 63.69|
|Beta (3Y monthly)||0.85|
|PE ratio (TTM)||14.91|
|Forward dividend & yield||1.64 (3.53%)|
|1y target est||N/A|
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
PRINCETON, N.J.--(BUSINESSWIRE)-- New data on Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases New ...
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It’s Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues. Today, more people who have been diagnosed with cancer are able to live with the disease than ever before.
Bristol-Myers Squibb Company will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 2:30 p.m.
Bristol-Myers Squibb Company today announced the Phase 3 CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase -unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.
Bristol-Myers Squibb Company (BMY) (“Bristol-Myers Squibb”) today announced that it priced its previously announced private offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $19 billion (collectively, the “Notes”). Bristol-Myers Squibb expects that the closing of the Offering will occur on May 16, 2019, subject to the satisfaction of customary closing conditions.
Bristol-Myers Squibb Company announced today that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation .
Bristol-Myers Squibb Company (BMY) (“Bristol-Myers Squibb”) today announced that, subject to market and other conditions, it intends to commence a private offering (the “Offering”) to sell senior unsecured notes (the “Notes”). The Offering is being conducted in connection with the previously announced proposed acquisition (the “Merger”) of Celgene Corporation (“Celgene”). Bristol-Myers Squibb expects to use the net proceeds from the Offering to fund a portion of the aggregate cash portion of the merger consideration to be paid to Celgene shareholders in connection with the Merger and to pay related fees and expenses, with any remaining proceeds being used for general corporate purposes.
NEW YORK-- -- Increases First Quarter Revenues 14% to $5.9 Billion Posts First Quarter GAAP EPS of $1.04 and Non-GAAP EPS of $1.10 Announces Shareholder Approval of Celgene Acquisition Presents Important New Data at American Association for Cancer Research and American College of Cardiology Annual Meetings Reaffirms Non-GAAP EPS Guidance Range of $4.10-$4.20 and Increases GAAP EPS Guidance Range to ...
PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative ...
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.
The U.S. Environmental Protection Agency (EPA) has recognized Bristol-Myers Squibb Company (BMY) with an ENERGY STAR® Partner of the Year Sustained Excellence Award for its outstanding contributions and leadership to improve the energy efficiency of facilities worldwide. Bristol-Myers Squibb has earned the ENERGY STAR® Partner of the Year award for the past five consecutive years. “We are proud to have our commitment to environmental responsibility recognized with the ENERGY STAR Partner of the Year Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, Bristol-Myers Squibb.
Analyses include the longest follow-up of lung cancer patients treated with Immuno-Oncology therapy in phase 3 randomized trials
Bristol-Myers Squibb Company (BMY) today announced that independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), recommend that Bristol-Myers Squibb shareholders vote “FOR” the approval of the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG).
Bristol-Myers Squibb Company’s (BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (CELG). In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibb’s website at www.bestofbiopharma.com and later today will file with the Securities and Exchange Commission (SEC) an investor presentation providing an overview of Bristol-Myers Squibb’s ability to derive value from Celgene’s pipeline and a Fact Sheet providing additional detail on key benefits of the transaction.
Bristol-Myers Squibb Company (BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (CELG). The investor presentation is available on the SEC’s website at www.SEC.gov and on Bristol-Myers Squibb’s website at https://www.bms.com/investors.html. The Celgene acquisition is a financially and strategically compelling transaction.
AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies
PRESS RELEASE 12 March 2019, 07:00 CET Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies ...
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company will take part in a fireside chat at the Barclays 2019 Global Healthcare Conference on Wednesday, March 13, 2019, in Miami. Charles Bancroft, executive vice president, Chief Financial Officer and Head of Global Business Operations, will answer questions at 12:30 p.m.
Bristol-Myers Squibb Company (BMY) today filed an investor presentation with the Securities and Exchange Commission (SEC), and the Board of Directors sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (CELG). The investor presentation underscores how the Celgene transaction is a compelling acceleration of Bristol-Myers Squibb’s ‘string-of-pearls’ approach to M&A and provides the best path for increased value creation.
Bristol-Myers Squibb Company will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 11:20 a.m.